UNSPSC 85416210: The diagnosis of abnormal findings in specimens from female genital organs : unspecified abnormal finding

In this classification, this covers the group of activities that yields a diagnosis of abnormal findings in specimens from female genital organs: unspecified abnormal finding. Abnormal findings in specimens from female genital organs: unspecified abnormal finding is listed In The World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10) as a four-character category under code R87.9.

UNSPSC 85416210, Diagnosis of abnormal findings in specimens from female genital organs (unspecified abnormal finding), is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three opportunities posted under this code in the source block address diagnostic imaging systems infrastructure (San Mateo Medical Center's PACS implementation), special education contracted services (Birdville Independent School District), and temporary health professional staffing across ancillary clinical categories (County of Santa Clara Health System). None of these solicitations concern diagnosis of abnormal findings in female genital specimens — the nominal scope of the code. The mismatch suggests the code has been applied inconsistently or incorrectly by issuing bodies, or that the procurement taxonomy does not capture the actual work being bought at state and local level under this classification.

The issuing bodies represented span a county health system, an independent school district, and a county-operated public hospital, indicating no particular concentration among jurisdiction types. Geographic activity appears in California (San Mateo and Santa Clara Counties) and Texas (Tarrant County), with response dates clustered in October 2026. The San Mateo Medical Center RFP (due October 21, 2026) and Santa Clara Health System qualification solicitation (due October 7, 2026) appear most recently posted, but neither corresponds to the pathology-based diagnostic code. The code does not support a meaningful pursue signal for firms in clinical diagnostics, specimen analysis, or pathology services.